Home Management of Mild‑to‑Moderate Hyperkalemia (Serum K⁺ ≈ 5.5 mmol/L)

Patient Selection & Initial Assessment

Asymptomatic patients with a serum potassium of 5.58 mmol/L and no ECG abnormalities can be managed at home, provided reversible causes are addressed and renal function is adequate (eGFR > 15 mL/min/1.73 m²)【1】【2】【3】.

The primary goal, according to the 2025 European Society of Cardiology (ESC) guidelines, is to normalize potassium by correcting reversible precipitating factors rather than stopping essential medications【1】【2】【4】.
Medications known to increase serum potassium should be reviewed: ACE inhibitors or ARBs (RAASi therapy), potassium‑sparing diuretics (e.g., spironolactone, eplerenone, amiloride, triamterene), NSAIDs, trimethoprim, heparin, and β‑blockers【3】.
Discontinuation of RAASi therapy as a first‑line measure increases mortality and hospitalizations; therefore, RAASi should be continued whenever possible【4】.
Temporary withholding of potassium‑sparing diuretics is advised when they are part of the regimen (if other sources confirm)【5】.
Patients should reduce dietary potassium intake during the acute phase; this includes limiting high‑potassium foods such as bananas, oranges, potatoes, tomatoes, avocados, dried fruits, and beans【1】【2】.

Serum potassium should be rechecked 5–7 days after initiating corrective measures, with concurrent monitoring of serum creatinine and magnesium【5】.
If potassium remains elevated, repeat testing every 5–7 days until values return to the normal range【5】.

When reversible causes have been addressed and potassium stays > 5.0 mmol/L, long‑term potassium‑binder therapy (e.g., patiromer or sodium zirconium cyclosilicate) should be considered instead of stopping life‑saving RAASi medications【1】【2】【4】.
The 2025 ESC guidelines state that, unless the underlying cause can be reversed, treatment for recurrent hyperkalemia will likely need to be indefinite【1】【2】.

Home management is not appropriate if any of the following are present:
- Serum potassium > 6.5 mmol/L (requires emergency treatment) – (not cited).
- Presence of ECG changes (e.g., peaked T‑waves, widened QRS) – (not cited).
- Symptomatic manifestations (muscle weakness, paralysis, palpitations) – (not cited).
- Severe renal impairment (eGFR < 15 mL/min/1.73 m²)【3】.

Do not discontinue RAASi therapy as the initial step; doing so raises mortality despite lowering potassium【4】.
Do not rely solely on dietary restriction when the patient is on multiple potassium‑retaining drugs; medication review is essential【1】【2】.
Do not delay follow‑up potassium measurement; rechecking within 5–7 days is critical for safe outpatient management【5】.

A serum potassium concentration of 5.8 mEq/L is classified as moderate hyperkalemia (5.5–6.0 mEq/L) by the European Society of Cardiology (ESC) classification system. 6, 7

In patients with chronic kidney disease, diabetes mellitus, or heart failure, potassium levels up to 6.0 mEq/L are often tolerated without arrhythmias when the elevation is identified incidentally on routine testing. 6

The first step in assessment is to exclude pseudo‑hyperkalemia by ensuring proper blood‑sampling technique; if pseudo‑hyperkalemia is suspected, the test should be repeated using careful venipuncture or arterial sampling. 6